Due to the extensive application of PARP inhibitors in the treatment of ovarian and breast cancer, PARP imaging technology holds promise for providing more optimized treatment options for patients with these cancers (Slade, 2020; Cortesi et al., 2021). The gene discussed is PARP1; the disease is breast carcinoma.